NR3C2 and metabolic dysfunction-associated steatotic liver disease: Antagonists of toll-like receptor 4 (ClinicalTrials.gov identifier: NCT02442687) and mineralocorticoid receptor (ClinicalTrials.gov identifier: NCT02923154) and inhibitors of semicarbazide-sensitive amine oxidase/vascular adhesion protein 1 (ClinicalTrials.gov identifier: NCT03166735) and PNPLA3 (ClinicalTrials.gov identifier: NCT04483947) have been proposed to have potential efficacy in NAFLD.